Figure 3.

Efficacy of mono-treatments and combination treatments on total brain Aβ. Animals were treated with BACE inhibitor RO5508887 at either 30 or 90 mg/kg daily (BI30, BI90), with anti-Aβ antibody gantenerumab (Gant) at 20 mg/kg weekly or with both compounds (BI30+Gant, BI90+Gant). Total brain Aβ was urea-extracted and Aβ42 (A) and Aβ40 (B) levels determined (A, B). Each bar represents the mean of 10–14 animals (+SD). BACE inhibition alone causes a dose-dependent decrease of brain Aβ40 and Aβ42, whereas mono-treatment with gantenerumab only decreases brain Aβ42. Combination treatment is significantly more efficacious on Aβ42 but only marginally enhances the reductions of Aβ40. The Aβ levels at baseline are included for comparison.